



BIOLOGICAL ACTIVITIES OF SALIVA EXTRACT
FROM THE MEDICINAL MALAYSIAN LEECH
HIRUDINARIA MANILLENSIS

BY

ABDUALRAHMAN M.ABDUALKADER

A thesis submitted in fulfillment of the requirement for
the degree of Master of Pharmaceutical Chemistry

Kulliyyah of Pharmacy
International Islamic University
Malaysia

MAY 2012

ABSTRACT

The work presented in this thesis describes selected biological activities of the salivary gland secretion of the medicinal Malaysian leech *Hirudinaria manillensis* (Lesson, 1842). A new device for leech feeding was developed using common laboratory tools consisting of a glass funnel wrapped with a parafilm membrane and filled with the phagostimulatory solution. Many phagostimulatory solutions were examined and only those containing sodium chloride and arginine were accepted by leeches. It was found that 71% of the tested leeches continued sucking for 15-45 min and 86% of them experienced 1-5 folds increments in body weight. For collection of a high quality and quantity LSE, we starved leeches for three weeks. A new method for LSE collection was described. The fed leeches were forced to regurgitate whatever they sucked by immersing them in ice containers. By using this method, leeches stayed alive and regain their activity after 15-30 min. The maximum concentration ($A_{280} = 0.342$) was provided within the first five minutes of sucking action. Gel electrophoresis (SDS-PAGE and Tricine-SDS-PAGE) methods revealed the existence of various peptides and proteins with molecular weights ranging from 2.3-250 kDa. Amidolytic activity assay showed that LSE inhibited thrombin-induced release of p-nitroanilide from the synthetic substrate S-2238 with IC_{50} of $49.391 \pm 2.219 \mu\text{g/ml}$. LSE was shown to prolong thrombin time *in vitro*. The maximum antithrombin activity was obtained during the dry season ($IC_{100} = 16.081 \pm 0.079 \mu\text{g/ml}$). A longer starvation period yielded a lower antithrombin activity. An optimization of lyophilization conditions revealed that pre-freezing at -20°C and a lyophilization cycle of 24 hours produced a dried leech saliva extract with antithrombin activity similar to that of the fresh extract. Findings also showed that the best stability was achieved when the lyophilized leech saliva extract was stored at -20°C in a dark place and glass tubes with loss of activity less than 10% during the study period of six months. Leech saliva showed an antibacterial activity against *Sal. typhi* and *S. aureus* with MIC of $78.353 \mu\text{g/ml}$ and against *E. coli* with MIC of $119.691 \mu\text{g/ml}$. Disc diffusion test showed that leech saliva extracted from 16-week starved leeches exhibited zones of inhibition of 22 and 25 mm against *Sal. typhi* and *E. coli*. Starvation period was found to have a serious impact on the antimicrobial activity of leech saliva. No activity was observed against the fungal strains, *C. albicans* and *C. neoformans*. Dose responsive curve of the DPPH free radical scavenging method showed an antioxidant activity of LSE with IC_{50} of $7.282 \mu\text{g/ml}$. The antidiabetic activity of subcutaneously injection of LSE (500 or 1000 $\mu\text{g/kg}$ b.w) significantly reduced blood glucose in alloxan-induced diabetic rats. LSE at the mentioned doses had no toxic events. The concurrent injection of LSE (250 $\mu\text{g/kg}$ b.w) and insulin (10 units/kg b.w) led to a good control in the glycemic states of the experimental rats with an instant decrease in blood glucose of 80-90% during the whole period of the study. Injection of LSE (250 $\mu\text{g/kg}$ b.w) one hour prior to alloxanisation (160 mg/kg b.w) prevented diabetes induction in the experimental rats. Nevertheless, double doses of alloxan produced mild diabetic states. Leech saliva extract exhibited a cytotoxic activity against small cell lung cancer (SW1271 cell line) with IC_{50} of $119.844 \mu\text{g/ml}$ compared to the IC_{50} values of two reference standard drugs, Irinotecan ($5.813 \mu\text{g/ml}$) and Carboplatin ($18.754 \mu\text{g/ml}$). LSE reduced the IC_{50} of Carboplatin and Irinotecan by 65% and 11.5% respectively. Carboplatin reduced the IC_{50} of LSE by 4.6%. Irinotecan was found to decline IC_{50} of LSE by 57%.

خلاصة البحث

تعتبر دودة العلق من الأدوات الطبية المستخدمة لعلاج الكثير من الأمراض البشرية منذ أقدم العصور وذلك لاحتواء لعابها على عدد كبير من المركبات الفعالة حيويًا، نذكر منها بشكل خاص البروتينات والبيبتيدات المضادة للتخثر. وقد احتل العلق حديثاً مكانة هامة في الجراحة التجميلية. تعيش دودة العلق في المناطق الدافئة والرطبة. يتألف جسمها من حلقات متتالية بالإضافة إلى محجمين أمامي (يستخدم لامتنصص الدم والثبت على جلد الفريسة) وخلفي (يستخدم للثبت والحركة). تتناول الأطروحة دراسة بعض التأثيرات العلاجية للعباب العلق الطبي الماليزي. لاستخلاص اللعاب من العلق بطريقة سهلة وكميات معتبرة تم تطوير جهاز جديد لتغذية العلق مؤلف من ورق البارافلم وقمع زجاجي مملوء بالسائل المغذي والذي تبين أنه يجب أن يحتوي على ملح كلور الصوديوم وحمض الأرجينين لكي يصبح غذاء مناسب للعلق. وجدنا خلال البحث أن 70% من العلق استمر بعملية الامتنصاص مدة تتراوح 15-45 دقيقة وأن 81% منهم أظهر 1-5 أضعاف زيادة في الوزن بعد الامتنصاص. لاستخلاص كميات معتبرة من اللعاب ذات نوعية عالية، تم تجويع العلق لفترة لا تقل عن ثلاث أسابيع. لأول مرة، تم استحداث طريقة علمية وآمنة للحصول على لعاب العلق عن طريق وضعهم في حمام ثلجي لإجبار العلق على الاستفراغ وهذه التقنية تستخدم لأول مرة في هذا البحث. تبين من خلال التجربة أن أكبر تركيز لمحتويات لعاب العلق تم الحصول عليه بعد 2-5 دقائق من بدء الامتنصاص. أظهرت نتائج الرحلان الكهربائي للعاب العلق وجود عدد كبير من البروتينات والبيبتيدات ذات وزن جزيئي يتراوح من 2.3-250 كيلو دالتون. بعد فحص الفعالية الحادة للرابطة البيبتيدية، تبين أن لعاب العلق قد ثبط قدرة الثرومبين على تحرير بارانتروانيليد من الركييزة الصناعية وذلك عند تراكيز 49.391 ± 2.219 ميكروغرام/مل. أظهرت النتائج أيضاً أن الفعالية العظمى للعاب العلق تم الحصول عليها خلال الفصل الجاف (16.081 ± 0.079 ميكروغرام/مل) وأن فترات التجويع الطويلة أعطت لعاب ذو فعالية ضعيفة (45.371 ± 0.553 ميكروغرام/مل بعد 26 أسبوع). أظهرت النتائج أيضاً أن لعاب العلق يجب ان يجمد في دراجة حرارة -20 درجة مئوية وأن يجفد لفترة لا تزيد عن 24 ساعة. فيما يتعلق ببياتية الخلاصة، تبين أن أفضل فعالية تم الحصول عليها عند حفظ العلق في درجة حرارة -20 درجة مئوية في إناء زجاجي بعيداً عن الضوء. كما تبين ان لعاب العلق يمتلك خواصاً مضادة لبعض السلالات الجرثومية كاسلمونيلا والزوائف الزنجارية (التركيز الأدنى الفعال 78.353 ميكروغرام/مل) والجرثيم القولونية (119.691 ميكروغرام/مل). وقد أثرت فترة التجويع على المكونات الفعالة في لعاب العلق حيث تبين أن اللعاب المستخلص بعد 26 أسبوع لا يمتلك خواصاً مضادة للجرثيم. وبالمقابل لم يظهر لعاب العلق أي فعالية تجاه السلالات الفطرية المستخدمة في التجربة. تم اختبار الفعالية المضادة للحذور الحرة عن طريق استخدام مولد للحذور الحرة، ووجد أن لعاب العلق يمتلك خواصاً مضادة للأكسدة عند تراكيز 7.282 ميكروغرام/مل. وللكشف عن فعالية لعاب العلق في مرض السكري تم حقن لعاب العلق في حيوانات تجرية أحدث فيها مرض السكري من النمط الاول مخبرياً بجرعات 500-1000 ميكروغرام/كغ تحت الجلد، فتبين أن له خواصاً حافظة لسكر الدم بدون تأثيرات سمية ملحوظة. وقد وجد أيضاً أن الإعطاء المتزامن للعاب العلق بجرعة 250 ميكروغرام/كغ تحت الجلد مع الأنسولين بجرعة 10 وحدة دولية/كغ تحت الجلد احدث ضبطاً جيداً لسكر الدم بانخفاض يتراوح من 80-90%. كما أن حقن لعاب العلق بجرعة 250 ميكروغرام/كغ تحت الجلد قبل حقن الألوكسان بجرعة 160 مغ/كغ في الجوف البريتواني قد منع حدوث مرض السكري عند حيوانات التجربة. أظهرت الدراسة ان لعاب العلق يمتلك تأثيراً قاتلاً للخلايا الصغيرة لسرطان الرئة عند تراكيز قاتلة لنصف الخلايا 119.844 ميكروغرام/مل. كما تبين أن لعاب العلق استطاع أن يخفف الجرعة الفعالة للكاربوبلاين و الأيرينوتكان بمقدار 65% و 11.5% على التوالي. مما سبق يمكن القول أن لعاب العلق يمتلك خواصاً طبية علاجية ذات أهمية بالغة في علاج بعض الأمراض المزمنة والمهددة للحياة، لذا نقترح بإجراء دراسات مكثفة أكثر على لعاب العلق لاستخلاص المركبات الفعالة وتحديد بنيتها وخواصها العلاجية بدقة.

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion; it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Pharmaceutical Chemistry.

.....

Supervisor

.....

Co-Supervisor

I certify that I have read this study and that in my opinion; it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Pharmaceutical Chemistry.

.....

Examiner

This thesis was submitted to the Department of Pharmaceutical Chemistry and is accepted as a fulfilment of the requirement for the degree of Master of Pharmaceutical Chemistry.

.....

Head of Department
Pharmaceutical Chemistry

This thesis was submitted to the Kulliyyah of Science and is accepted as a fulfilment of the requirement for the degree of Master of Pharmaceutical Chemistry.

.....

Dean, Kulliyyah of Pharmacy

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Abdualrahman M.Abdualkader

Signature.....

Date.....

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION
OF FAIR USE OF UNPUBLISHED RESEARCH**

Copyright © 2012 by International Islamic University Malaysia. All rights reserved.

**BIOLOGICAL ACTIVITIES OF SALIVA EXTRACT FROM THE MEDICINAL
MALAYSIAN LEECH *HIRUDINARIA MANILLENSIS***

I hereby affirm that The International Islamic University Malaysia (IIUM) holds all rights in the copyright of this work and henceforth any reproduction or use in any form or by means whatsoever is prohibited without the written consent of IIUM. No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder.

Affirmed by Abdualrahman M.Abdualkader

.....
Signature

.....
Date

To my beloved and respected family, thank you all for your kind support love and care. Special thank to you dear great mum, your selfless spiritual imparted moral support have always been with me helping me in achieving my goals. Tons of thanks to my beloved dad, you've sacrificed both personally and professionally for me to chase down my dreams. Islamic motivations, and all such beautiful words that always come out of your mouths that stir the love of Allah Almighty and His Most beloved Messenger Muhammad (SAW) in the depth of my heart, I hope you know how much it has meant to me and how important you are to me, blessings of Allah (SWA) be always with your souls of the lovers of Prophet Muhammad SAW.

ACKNOWLEDGEMENTS

Beginning is always starting by praising Allah (SWA) Almighty, and may His peace and blessings be upon our beloved prophet Muhammad (SAW).

Time has come to express my sincere gratitude to my supervisors Prof. Dr. Abbas Mohamad Ghawi and Asco. Prof. Ahmed Merzouk for their invaluable advice, and guidance throughout the course of my study and research for the degree of Master of Science. They take care of me from my study life to personal development, give me lots of opportunity to explore and to learn and provide me the freedom and flexibility to be creative with my work and at the same time pushing me to expand my productivity and knowledge beyond what I thought possible. Always provide me with insight in knowledge and encourage me to apply appropriate methodology in my research. In fact, you are chapters in my life that I will look back on with fond memories and I look forward to the many chapters that lie ahead both as your friend and student. May Allah (SWA) bless both of you and your family abundantly.

Real motivations and inspirations especially if it comes to academic field is the responsibility of Dr. Abubakar Abdullahi Kebbe, it has been a pleasure and an honour to be with you. In fact your constant words of encouragement provided me confidence to excel.

You deserved to be acknowledged dear research colleague, Mohamed Alaama, you have always been willing to lend a helping hand, having such wonderful team is a proud. Am grateful to Sir. Noor Zihan Binti Abdul Karim, Science officer, Pharmaceutical Chemistry Department for all your help in chemical supply and managing our laboratory. The same thanks go to all laboratory technicians: Br. Mohd Razif, Br. Mohd Najib, Sir. Fatimah and Sir. Azura.

I have to express my word of thanks to the entire staff of Pharmaceutical Chemistry Department for their help support and scholarly advice. Most especially to our former head of the department Dr. Mohammed B. Awang who has always been with us to give us constructive advices, so also the present Head, Department of Pharmaceutical Chemistry, Dr. Siti Zaiton Binti Mat So'ad, who has always been there to oblige our request and optimize our laboratory standard.

Same acknowledgement goes to you all dear friends, whose name were not mentioned, this is just due to a space alert however feelings of appreciations have always been with you.

Tons of thanks to research management center (RMC) International Islamic University Malaysia allocating fund to this research which eventually led us to carry out an effective and successful output.

Finally I would like to thank Aleppo University, Syria for offering me scholarship that provided me an opportunity to advance my education and professional development beyond the field of Chemistry at Kulliyah of Pharmacy, International Islamic University Malaysia.

Abdualrahman M.Abdualkader

TABLE OF CONTENTS

Abstract	i
Abstract in Arabic	ii
Approval page	iv
Declaration	v
Copyright	vi
Dedication	vii
Acknowledgements	viii
List of Tables	xvi
List of Figures	xix
List of Abbreviations	xxiii
CHAPTER ONE: INTRODUCTION	1
1.1. Background and Justification	1
1.2. Research Hypothesis	2
1.3. Problem of the Statement	2
1.4. Research Objectives	3
CHAPTER TWO: LITERATURE REVIEW	5
2.1. Leeches	5
2.1.1. Introduction	5
2.1.2. Leech Morphology and Taxonomy	5
2.1.3. Leech Feeding Biology	8
2.1.4. Leech Locality and Ecology	8
2.2. The Therapeutical Application of Leeching	9
2.2.1. Introduction	9
2.2.2. Leech Therapy in the History	9
2.2.3. The Modern Applications of Leech Therapy	13
A. Cardiovascular Diseases (CVDs)	13
B. Diabetes Mellitus	14
C. Cancer	14
D. Other Applications of Leech Therapy	15
Reconstructive Surgery	15
Dental Abnormalities	15
Audiology and Ear Disorders	16
Skin Illnesses	16
Analgesic	17
2.2.4. Leech Therapy Complications	17
2.2.5. Leech Therapy Contraindications	18
2.2.6. The Medicinal Malaysian Leech and its Applications	18
2.3. The Anticoagulant Activity of Leech Salivary Gland Secretion	20
2.3.1. Introduction	20
2.3.2. The Coagulation System of Human Body	21
A. Terms and Definitions	21

B. The Mechanism of Blood Clot Formation	22
C. The Regulation of Blood Hemostasis.....	22
2.3.3. The Anticoagulant Drugs	23
2.3.4. Leech-derived Anticoagulant Peptides and Proteins	25
A. Leech Thrombin Inhibitors	25
B. Other Anticoagulant Peptides and Proteins Isolated from Leech Species.....	26
2.3.5. Leech Salivary Secretion and Its Components in Clinical Practice...	26
A. Cardiovascular Diseases (CVDs)	26
B. Microsurgery	27
2.3.6. The Prevalence of Cardiovascular Diseases	28
2.4. The Antimicrobial Activity of Leech Salivary Gland Secretion	29
2.4.1. Introduction.....	29
2.4.2. Leech Therapy and Leech Products as Antimicrobial Agent	30
2.5. Antioxidants as Prophylactic and Therapeutic Agents	32
2.5.1. Introduction.....	32
2.5.2. The Medical Importance of Antioxidants	32
A. Cardiovascular Diseases (CVDs).....	33
B. Cancer and Metastasis.....	34
C. Diabetes Mellitus.....	34
D. Other Applications.....	35
2.6. Diabetes Mellitus.....	35
2.6.1. Definition	35
2.6.2. The Global Predominance of Diabetes Mellitus.....	35
2.6.3. Diabetes Mellitus in Malaysia	36
2.6.4. Type 1 Diabetes Mellitus (T1DM).....	37
A. Etiology of T1DM.....	37
B. Signs and Symptoms of T1DM	37
2.6.5. Type 2 Diabetes Mellitus (T2DM).....	38
A. Etiology of T2DM.....	38
B. Signs and Symptoms of T2DM	38
2.6.6. Other Types of Diabetes Mellitus and Their Etiology.....	38
2.6.7. Diagnosis.....	39
2.6.8. Oral Hypoglycemic Agents.....	44
2.6.9. Insulin Preparation	42
2.6.10. Medication.....	42
A. Patients with type 2 Diabetes Mellitus	43
B. Patients with type 1 Diabetes Mellitus.....	43
2.6.11. Leech Therapy in Diabetes Mellitus	43
2.7. Cancer and Metastasis	46
2.7.1. Introduction.....	46
2.7.2. The Global Predominance of Cancer.....	46
2.7.3. The Prevalence of Cancer in Asia-Pacific Region and Malaysia	46
2.7.4. Leech Therapy in Cancer and Metastasis	47
2.8. Peptides and Proteins	48
2.8.1. Definition	48
2.8.2. Protein Concentration Estimation Methods	48
A. Ultraviolet Absorption Methods (A_{280} , A_{205}).....	48
B. Colorimetric Methods.....	49

2.8.3. Peptides and Proteins Characterization Using Polyacrylamide Gel Electrophoresis Techniques (PAGE)	49
--	----

CHAPTER THREE: MATERIALS AND METHODS	52
3.1. Leech Feeding	52
3.1.1. Leech Sampling and Maintenance	52
3.1.2. Leech Identification (taxonomy).....	52
3.1.3. Chemicals, Reagents and Instrumentations	54
3.1.4. Leech Feeding Device.....	55
3.1.5. Leech Feeding Behavior	56
A. Starvation Period	56
B. Leech Response to Different PhSs	57
C. The Relationships between the Initial Leech Body Weight and Sucking Period/ Body Weight Gain After Sucking	57
3.2. Leech Saliva Extract Collection and Total Protein Estimation	58
3.2.1. Collection of Leech Saliva Extracts (LSE).....	58
3.2.2. Total Protein Estimation in LSE	60
A. UV Absorbance at 280nm.....	60
B. Bradford Assay Method.....	60
3.2.3. The Relationship between Total Protein Content in LSE and Sucking Period.....	61
3.2.4. Statistical Analysis.....	61
3.3. Determination of the Molecular Weights of Leech Saliva Extract Peptides and Proteins (LSE-P/P)	62
3.3.1. Chemicals, Reagents and Instrumentation	62
3.3.2. Buffers, Reagents and Stock Solutions Preparation	63
3.3.3. Assembling of the Device and Working Procedures	65
3.3.4. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) Method	67
3.3.5. Tricine-SDS-PAGE Method	68
3.3.6. Calculations and Determination of Molecular Weights.....	69
3.4. The Anticoagulant Activity of Leech Saliva Extract.....	69
3.4.1. Chemicals, Reagents and Instrumentation	69
3.4.2. Leech Saliva Extract Collection.....	70
3.4.3. Total Protein Estimation	70
3.4.4. Amidolytic Activity of LSE.....	70
3.4.5. Antithrombin Activity of Freshly Collected LSE.....	71
3.4.6. The Effects of Starvation Period and Seasonal Difference on the Antithrombin Activity of Fresh LSE.....	73
3.4.7. The Effects of Lyophilization Conditions and Lyophilization-vessel Type on the Antithrombin Activity of LSE.....	74
3.4.8. The Effects of Storage Conditions and Type of Storage Container on the Antithrombin Activity of LSE	74
3.4.9. Statistical Analysis.....	74
3.5. The Antimicrobial Activity of Leech Saliva Extract.....	75
3.5.1. Chemicals, Reagents and Instrumentation	75
3.5.2. Leech Saliva Extract Collection.....	75
3.5.3. Total Protein Estimation.....	76
3.5.4. Microbial Strains.....	76

3.5.5. Media Preparation	76
3.5.6. Petri Dish Preparation	77
3.5.7. Adjustment of Microorganism Number and Inoculums Preparation	78
3.5.8. Disc Diffusion Test	79
3.5.9. Broth Microdilution Test	81
3.6. The Antioxidant Activity of Leech Saliva Extract	82
3.6.1. Chemicals, Reagents and Instrumentation	82
3.6.2. Leech Saliva Extract Collection	82
3.6.3. Total Protein Estimation	83
3.6.4. Free Radical Scavenging Activity	83
3.7. The Antidiabetic Activity of Leech Saliva Extract	85
3.7.1. Chemicals, Reagents and Instrumentation	85
3.7.2. Experimental Animals	85
3.7.3. Leech Saliva Extract Collection	86
3.7.4. Total Protein Estimation	87
3.7.5. The Hypoglycemic Activity of LSE	87
A. Induction of Experimental Alloxan-Induced Diabetes	87
B. Experimental Designs	88
C. Toxicity Evaluation	89
D. Histological Examination	89
E. Statistical Analysis	89
3.7.6. The Prophylactic Activity of LSE against Type1-Like Diabetes Induced by Alloxan	90
A. Experimental Design	90
B. Statistical Analysis	91
3.8. The Cytotoxic Activity of Leech Saliva Extract	91
3.8.1. Chemicals, Reagents and Instrumentation	91
3.8.2. Leech Saliva Extract Collection	92
3.8.3. Total Protein Estimation	92
3.8.4. Cancer Cell Line and Culture	93
3.8.5. Cell Harvesting	93
3.8.6. Cell Viability and Counting	94
3.8.7. Cell Subculturing	94
3.8.8. The Antiproliferative Activity of Leech Saliva Extract	95
3.8.9. <i>In vitro</i> Cytotoxicity Assay	96
CHAPTER FOUR: RESULTS	98
4.1. Leech Feeding	98
4.1.1. Leech Identification (Taxonomy)	98
4.1.2. Leech Feeding Device	98
4.1.3. Leech Feeding Behavior	98
A. Starvation Period	98
B. Leech Response to Different Phagostimulatory Solutions	98
C. The Relationship between the Initial Leech Body Weight and Sucking Period	99
D. The Relationship between the Initial Leech Body Weight and Weight Gain after Sucking	100
4.2. Leech Saliva Extract Collection and Total Protein Estimation	101
4.2.1. Leech Saliva Extract Collection	101

4.2.2. The Relationship between the Total Protein Content in LSE and Sucking Period	101
4.3. Determination the Molecular Weights of Leech Saliva Extract Peptides and Proteins (LSE-P/P)	104
4.3.1. SDS-PAGE Methods.....	104
4.3.2. Tricine-SDS-PAGE.....	107
4.4. The Anticoagulant Activity of Leech Saliva Extract.....	113
4.4.1. Total Protein Estimation of the Collected LSE.....	113
4.4.2. Amidolytic Activity of LSE.....	116
4.4.3. Antithrombin Activity of Freshly Collected LSE.....	117
4.4.4. The Effects of Starvation Period and Seasonal Difference on the Antithrombin Activity of Fresh LSE.....	119
4.4.5. The Effects of Lyophilization Conditions and Lyophilization-Vessel Type on the Antithrombin Activity of LSE	122
4.4.6. The Effects of Storage Conditions and Type of Storage Container on the Antithrombin Activity of LSE	125
A. Antithrombin Activity of LSE Stored at Room Temperature	125
B. Antithrombin Activity of LSE Stored at +4°C.....	128
C. Antithrombin Activity of LSE Stored at -20°C.....	131
4.5. The Antimicrobial Activity of Leech Saliva Extract	133
4.5.1. Total Protein Estimation of the Collected LSE.....	133
4.5.2. Disc Diffusion Test	134
4.5.3. Broth Microdilution Test	138
4.6. The Antioxidant Activity of Leech Saliva Extract	139
4.6.1. Total Protein Estimation of the Collected LSE.....	139
4.6.2. Free Radical Scavenging Activity	141
4.7. The Antidiabetic Activity of Leech Saliva Extract.....	142
4.7.1. Leech Saliva Extraction and Total Protein Estimation	142
4.7.2. The Hypoglycemic Activity of Leech Saliva Extract	144
A. Leech Saliva Extract as Antihyperglycemic Agent.....	144
B. Toxicity Evaluation	151
C. Histological Examination	151
4.7.3. The Prophylactic Activity of LSE against Type1-Like Diabetes Induced by Alloxan	151
4.8. The Cytotoxic Activity of Leech Saliva Extract.....	153
4.8.1. Leech Saliva Extraction	153
4.8.2. Total Protein Estimation in Leech Saliva Extract.....	153
4.8.3. Cell Harvest and Counting.....	155
4.8.4. The Cytotoxic /Anti-Proliferation Activity of Leech Saliva Extract.	155
CHAPTER FIVE: DISCUSSION.....	165
5.1. Leech Feeding	165
5.1.1. Leech Identification (Taxonomy)	165
5.1.2. Leech Feeding Device.....	165
5.1.3. Leech Feeding Behavior	167
A. Starvation Period	167
B. Leech Response to Different Phagostimulatory Solutions.....	168
C. The Relationships between the Initial Leech Body Weight, Sucking Period and Weight Gain after Sucking.....	169

5.2. Leech Saliva Extract Collection and Total Protein Estimation	170
5.2.1. Leech Saliva Extract Collection.....	170
5.2.2. The Relationship between the Total Protein Content in LSE And Attachment Period.....	171
5.3. The Molecular Weights of Leech Saliva Extract Peptides and Proteins ...	172
5.4. The Anticoagulant Activity of Leech Saliva Extract.....	178
5.4.1. The Amidolytic Activity of Leech Saliva Extract	178
5.4.2. The Antithrombin Activity of Freshly Collected Leech Saliva Extract	179
5.4.3. The Effects of Starvation Period and Seasonal Difference on the Antithrombin Activity of Fresh Lse.....	180
5.4.4. The Effects of Lyophilization Conditions and Lyophilization- Vessel Type on the Antithrombin Activity of LSE	182
5.4.5. The Effects of Storage Conditions and Storage Container Type on the Antithrombin Activity of LSE	184
5.5. The Antimicrobial Activity of Leech Saliva Extract.....	186
5.6. The Antioxidant Activity of LSE.....	190
5.7. The Antidiabetic Activity of Leech Saliva Extract.....	193
5.7.1. The Hypoglycemic Activity of Leech Saliva Extract	193
5.7.2. Toxicity Evaluation.....	197
5.7.3. The Prophylactic Activity of LSE Against Type-1 Diabetes Mellitus Induced by Alloxan.....	198
5.8. The Cytotoxic Activity of Leech Saliva Extract.....	199
5.8.1. Growth Inhibitory Effect of LSE on Small Cell Lung Cancer SW1271	199
5.8.2. Leech Saliva Extract in Combination with Other Cytotoxic Agents.	202
CHAPTER SIX: CONCLUSION	205
BIBLIOGRAPHY	207

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
2.1	Coagulation factors	21
2.2	General outlines of anticoagulant drugs	24
2.3	Leech-derived thrombin inhibitors LDTIs	25
2.4	Other types of diabetes mellitus	39
2.5	Oral hypoglycemic agents	41
2.6	Insulin preparations and their properties	42
3.1	The phagostimulatory solutions used for leech feeding	57
3.2	Buffers, reagents and stock solutions preparation for gel electrophoresis	64
4.1	The relationship between total protein concentration in LSE and sucking period	103
4.2	The molecular weights of LSE-P/P separated by 15%SDS-PAGE	105
4.3	The molecular weights of LSE-P/P separated by 16%SDS-PAGE	107
4.4	The molecular weights of LSE-P/P separated by 16.5%Tricine-SDS-PAGE	109
4.5	The molecular weights of LSE-P/P separated by 18%Tricine-SDS-PAGE	111
4.6	The molecular weights of LSE-P/P separated by 20%Tricine-SDS-PAGE	113
4.7	Total protein concentration of LSE collected from four groups of leeches starved for different periods	115
4.8	Amidolytic activity of leech saliva extract	117
4.9	The antithrombin activity of fresh leech saliva extract	118
4.10	The effects of starvation period and seasonal difference on the antithrombin activity of fresh LSE	120

4.11	The effects of lyophilization conditions (pre-freezing and type of container) on the antithrombin activity of LSE	122
4.12	The effects of lyophilization time on the antithrombin activity of LSE	124
4.13	Total protein concentration of LSE collected from leeches starved for 16 and 22 weeks	134
4.14	The antimicrobial activity of LSE	135
4.15	Broth microdilution test for LSE	139
4.16	Total protein concentration of LSE collected for the investigation of the antioxidant activity	140
4.17	DPPH free radical scavenging activity of LSE	141
4.18	DPPH free radical scavenging activity of L-ascorbic acid (Vit.C)	142
4.19	Total protein concentration of the LSE collected for the investigation of the hypoglycemic activity of LSE	144
4.20	Effect of different doses of leech saliva extract and insulin on fasting blood glucose (mmol/L) in normal and diabetic rats at various time intervals (hours)	146
4.21	Percentage decrease in FBG in diabetic rats injected with leech saliva extract subcutaneously	150
4.22	The prophylactic activity of LSE against type1-like DM induced by alloxan	152
4.23	Total protein concentration of LSE collected for the investigation of the cytotoxic activity	154
4.24	The cytotoxic activity of LSE on human small lung cancer (SW1271 cell line)	156
4.25	The cytotoxic activity of irinotecan on human small lung cancer (SW1271 cell line)	157
4.26	The cytotoxic activity of carboplatin on human small lung cancer (SW1271 cell line)	158
4.27	The cytotoxic activity of PhS on human small lung cancer (SW1271 cell line)	159
4.28	The cytotoxic activity of LSE combined with irinotecan on human small lung cancer (SW1271 cell line)	163

4.29	The cytotoxic activity of LSE combined with carboplatin on human small lung cancer (SW1271 cell line)	164
5.1	A Comparison of the molecular weights of the peptides and proteins in LSE of the Malaysian leech, <i>H. manillensis</i> , with literature data	174

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
2.1	Leech taxonomy	6
2.2	The European medicinal leech	7
2.3	Laboratory test for diagnosis of diabetes mellitus	40
3.1	The medicinal Malaysian leech <i>Hirudinaria manillensis</i> . A: Dorsal view; B: Ventral view	53
3.2	The medicinal Malaysian leech <i>Hirudinaria manillensis</i> . A: Posterior sucker; B: Anterior sucker	54
3.3	Leeches being fed using feeding device consisting of parafilm membrane stretched across a glass funnel filled with the phagostimulatory solution of 0.001M arginine in normal saline	56
3.4	Leech saliva extract collection. A: The engorged leeches fed on the phagostimulatory solution; B: Leeches kept in plastic containers immersed in ice; C: The paralyzed leeches after the ice-cold bath with the vomited LSE	59
3.5	Mini-Protean Tetra Cell Gel Electrophoresis Apparatus (Bio-Rad)	63
3.6	MIC determination using broth microdilution test	82
4.1	The relationship between the initial leech body weight and sucking period	99
4.2	The relationship between the initial leech body weight and weight gain after sucking	100
4.3	The relationship between total protein concentration in LSE and sucking period	103
4.4	Separation of LSE-P/P by 15%SDS-PAGE	104
4.5	Standard curve of the protein markers separated by 15% SDS-PAGE	105
4.6	Separation of LSE-P/P by 16%SDS-PAGE	106
4.7	Standard curve of the protein markers by 16%SDS-PAGE	106

4.8	Separation of LSE-P/P by 16.5%Tricine-SDS-PAGE	108
4.9	Standard curve of the ultra-low molecular weight peptide markers by 16.5%Tricine-SDS-PAGE	108
4.10	Separation of LSE-P/P by 18%Tricine-SDS-PAGE	110
4.11	Standard curve of the ultra-low molecular weight peptide markers by 18%Tricine-SDS-PAGE	110
4.12	Separation of LSE-P/P by 20%Tricine-SDS-PAGE	112
4.13	Standard curve of the ultra-low molecular weight peptide markers by 20%Tricine-SDS-PAGE	112
4.14	The standard curve for total protein estimation of LSE1 collected from 5-week starved leeches	114
4.15	The standard curve for total protein estimation of LSE2, 3 and 4 starved for 16, 22, and 26 weeks, respectively	114
4.16	Time-dependent amidolytic activity of leech saliva extract	116
4.17	The dose responsive curve of the amidolytic activity of leech saliva extract	117
4.18	The antithrombin activity of freshly collected LSE	118
4.19	The effects of starvation period and seasonal difference on the antithrombin activity of fresh LSE	121
4.20	The effects of starvation period and seasonal difference on the antithrombin activity of fresh LSE	121
4.21	The effects of lyophilization conditions (pre-freezing and type of container) on the antithrombin activity of LSE	123
4.22	The effect of lyophilization time on the antithrombin activity	124
4.23	The antithrombin activity of LSE stored at room temperature	127
4.24	The antithrombin activity of LSE stored at +4°C	130
4.25	The antithrombin activity of LSE stored at -20°C	132
4.26	Standard curve for total protein estimation of LSE collected from leeches starved for 16 and 22 weeks	133
4.27	Antibacterial activity of LSE against <i>Sal. typhi</i> . A: discs loaded with LSE from 16-weeks starved leeches (zone of inhibition 22mm); B: reference antibiotic-containing discs (5µg ciprofloxacin/disc)	136

4.28	Antibacterial activity of LSE against <i>Sal. typhi</i> . A: discs loaded with LSE from 22-weeks starved leeches (zone of inhibition 10mm); B: reference antibiotic-containing discs (5µg ciprofloxacin/disc)	136
4.29	Antibacterial activity of LSE against <i>S. aureus</i> . A: discs loaded with LSE from 22-weeks starved leeches (zone of inhibition 11mm); B: reference antibiotic-containing discs (5µg ciprofloxacin/disc)	137
4.30	Antibacterial activity of LSE against <i>E. coli</i> . A: discs loaded with LSE from 22-weeks starved leeches (no zone of inhibition); B: reference antibiotic-containing discs (5µg ciprofloxacin/disc)	138
4.31	The standard curve for total protein estimation of LSE collected for the investigation of the antioxidant activity	140
4.32	Dose responsive curve of DPPH free radical scavenging activity of LSE	141
4.33	Dose responsive curve of DPPH free radical scavenging activity of L-ascorbic acid (Vit.C)	143
4.34	Standard curve for total protein estimation in LSE collected for the investigation of the hypoglycemic activity	143
4.35	Effect of different doses of leech saliva extract and insulin on fasting blood glucose (mmol/L) in normal and diabetic rats at various time intervals (h)	147
4.36	Effect of different doses of leech saliva extract and insulin on fasting blood glucose (mmol/L) in normal and diabetic rats at various time intervals (h)	148
4.37	Percentage decrease in FBG in diabetic rats injected s.c. with leech saliva extract, insulin and LSE-insulin mixture	150
4.38	The prophylactic activity of LSE against type1-like DM induced by alloxan	153
4.39	The standard curve for total protein estimation of LSE collected for the investigation of the cytotoxic activity	154
4.40	Dose responsive curve of the cytotoxic activity of serial double dilutions of leech saliva extract on human small lung cancer (SW1271 cell line)	156
4.41	Dose responsive curve of the cytotoxic activity of serial double dilutions of irinotecan on human small lung cancer (SW1271 cell line)	157
4.42	Dose responsive curve of the cytotoxic activity of serial double dilutions of carboplatin on human small lung cancer (SW1271	158

	cell line)	
4.43	Dose responsive curve of the cytotoxic activity of serial double dilution of 10×PhS on human small lung cancer (SW1271 cell line)	159
4.44	A comparison between the cytotoxic activity of leech saliva extract, Irinotecan and Carboplatin on small cell lung cancer (SW1271 cell line)	160
4.45	A comparison between the cytotoxic activity of leech saliva extract, Irinotecan and Carboplatin on small cell lung cancer (SW1271 cell line)	161
4.46	Dose responsive curve of the cytotoxic activity of serial double dilutions of a mixture of LSE and Irinotecan	163
4.47	Dose responsive curve of the cytotoxic activity of serial double dilution of a mixture of LSE and Carboplatin	164

LIST OF ABBREVIATIONS

ADP	adenosine diphosphate
AMP	antimicrobial peptide
AMPs	antimicrobial peptides
AMR	resistance to antimicrobial agent
APS	ammonium persulfate
ATIII	antithrombin III
b.w	body weight
BSA	bovine serum albumin
CAT	catalase
CFU	colony forming unit
CGM	complete growth media
CHD	coronary heart disease
CSII	continuous subcutaneous insulin infusion
CVDs	cardiovascular diseases
DM	diabetes mellitus
DTIs	direct thrombin inhibitors
DVT	deep venous thrombosis
FBG	Fasting blood glucose
FBS	fetal bovine serum
FDA	Food and Drug Administration
FIIa	activated coagulation Factor II (thrombin)
FXa	factor Xa
GLM	general linear model
GPx	glutathione dismutase
GSH	glutathione
5-HT	serotonin
HIT	heparin-induced thrombocytopenia
HMWH	high molecular weight heparin
i.p	intraperitoneal
IDDM	insulin-dependent diabetes mellitus
IDTIs	indirect thrombin inhibitors
IGT	impaired glucose tolerance
LMWh	low molecular weight heparins
LPS	lipopolysaccharides
10×LSE	ten times concentrated leech saliva extract
3×LSE	three times concentrated leech saliva extract
LSE	leech saliva extract
LSE-P/P	leech saliva extract peptides and proteins
MeOH	methanol
MHA	Mueller-Hinton agar

MHB	Mueller-Hinton broth
MIC	minimal inhibitory concentration
MIDD	maternally inherited diabetes and deafness
MODY	maturity-onset of diabetes of the young
NIDDM	insulin-independent diabetes mellitus
OD	optical density
OGTT	oral glucose tolerance test
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffer saline
PBS-BSA	bovine serum albumin- phosphate buffer saline
PDA	potato dextrose agar
PDB	potato dextrose broth
pen/strep	penicillin/streptomycin
10×PhS	ten times concentrated phagostimulatory solution
PhS	phagostimulatory solution
PhS1	phagostimulatory solution of 0.001M arginine in normal saline
PhSs	phagostimulatory solutions
PPAR- γ	peroxisome proliferator-activated receptor-gamma
R _f	mobility index
ROS	reactive oxygen species
s.c	subcutaneously/subcutaneous
SD	standard deviation
SDS	sodium dodecyl sulfate
SDS-PAGE	sodium dodecyl sulfate- Polyacrylamide Gel electrophoresis
SEM	standard error of the mean
SOD	superoxide dismutase
SPSS	statistical Program for Social Sciences
T _{eut}	eutectic melting temperature
T1DM	type 1 diabetes mellitus
T2DM	type 2 diabetes mellitus
TEMED	N,N,N',N'-tetramethylethylenediamine
TFPI	tissue factor pathway inhibitor
T _g	glass transition temperature
TT	thrombin time
%TT	percentage increase in thrombin time
Tzds	thiazolidinediones
UFH	unfractionated heparin
vWF	von Will brand factor
WHO	World Health Organisation
β -ME	β -mercaptoethanol